Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud.

ABSTRACT:

Background

Ivermectin is an antiparasitic drug being investigated in clinical trials for the prevention of COVID-19. However, there are concerns about the quality of some of these trials.

Objectives

To conduct a meta-analysis with randomized controlled trials of ivermectin for the prevention of COVID-19, while controlling for the quality of data. The primary outcome was RT-PCR-confirmed COVID-19 infection. The secondary outcome was rate of symptomatic COVID-19 infection.

Methods

We conducted a subgroup analysis based on the quality of randomized controlled trials evaluating ivermectin for the prevention of COVID-19. Quality was assessed using the Cochrane risk of bias measures (RoB 2) and additional checks on raw data, where possible.

Results

Four studies were

SUBMITTER: Hill A 

PROVIDER: S-EPMC9326581 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature